Eisai Company, Ltd.
4-6-10 Koishikawa, Bunkyo-ku
336 articles with Eisai Company, Ltd.
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Biogen and Eisai, Co., Ltd. announced that the U.S. Food and Drug Administration has granted accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities
Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a research collaboration agreement that initially aims to help address the significant unmet needs of people living with Alzheimer's disease, especially those experiencing the earliest stages of the disease, known as Mild Cognitive Impairment.
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease
Biogen and Eisai, Co., Ltd. announced that Biogen has submitted a Japanese New Drug Application to the Ministry of Health, Labor and Welfare for aducanumab, an investigational therapy for Alzheimer’s disease.
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease andto meaningfully change the course of Alzheimer’s disease
Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
Eisai Co., Ltd. and Cogstate, Ltd. announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the "Cogstate Brief BatteryTM" for use in healthcare and other markets.
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health.
GCAR, Eisai and UPMC, on Behalf of REMAP-CAP Investigator Network, Announce Eritoran’s Inclusion in REMAP-COVID, An Adaptive Clinical Trial to Test Interventions for Patients With Moderate and Severe COVID Infection
Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology
Numab Therapeutics announced the closing of its Series B financing round at a total volume of CHF 22M. New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella.
Eisai indicated it was voluntarily withdrawing the drug, but in a statement noted it disagreed with the FDA’s interpretation of the data and believes the drug’s benefits outweigh the cancer risk.
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation
Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-house developed antiepileptic drug Fycompa for an additional indication for monotherapy of partial-onset seizures and an additional indication for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.
Non-Sedative Orexin Receptor Antagonist Proven Effective for Both Sleep Onset and Sleep Maintenance With No Meaningful Differences Between Dayvigo and Placebo on Next-Day Postural Stability or Memory and Improvement of Daily Functioning
In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom are affected by partial-onset seizures.
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis
The clinical trials the approval is based on suggested the drug was effective for treating primary insomnia but may also be effective for insomnia associated with other diseases, such as depression.
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
Eisai Co., Ltd. announced that the latest information on its in-house discovered and developed eribulin mesylate will be presented during the 42nd San Antonio Breast Cancer Symposium.
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference
Eisai Co., Ltd. announced today that three oral presentations and eight poster presentations, highlighting the latest data on its Alzheimer's disease / dementia pipeline including anti-amyloid beta (Abeta) protofibril antibody BAN2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzheimer's disease (AD